1. 1) Hussaarts L., Muhlebach S., Shah V. P., McNeil S., Borchard G., Fluhmann B., Weinstein V., Neervannan S., Griffiths E., Jiang W., Wolff-Holz E., Crommelin D. J. A., de Vlieger J. S. B., Ann. N. Y. Acad. Sci., 1407, 39–49 (2017).
2. 2) Klein K., Stolk P., De Bruin M. L., Leufkens H. G. M., Crommelin D. J. A., De Vlieger J. S. B., Eur. J. Pharm. Sci., 133, 228–235 (2019).
3. 3) Wang Y., Grainger D. W., Front. Drug Deliv., 2, 901281 (2022).
4. 4) Ministry of Health, Labour and Welfare. “Guideline for the Development of Liposome Drug Products.”: 〈https://www.nihs.go.jp/drug/section4/160328_MHLW_liposome_guideline.pdf〉, cited 21 April, 2023.
5. 5) Food and Drug Administration. “Liposome drug products chemistry, manufacturing, and controls; human pharmacokinetics and bioavailability; and labeling documentation guidance for industry.”: 〈https://www.fda.gov/media/70837/download〉, cited 21 April, 2023.